Publications (48) Anna Vilalta Lacarra publications

filter_list

2025

  1. Correction to: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours (Nature, (2025), 637, 8048, (1218-1227), 10.1038/s41586-024-08305-z)

    Nature

  2. Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data

    Cancer Immunology, Immunotherapy, Vol. 74, Núm. 4

  3. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

    Nature, Vol. 637, Núm. 8048, pp. 1218-1227

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. "What medical students with better academic results do: a cross-sectional analysis"

    BMC medical education, Vol. 23, Núm. 1, pp. 19

  2. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  3. Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study

    Frontiers in Psychology, Vol. 14

  4. Biología celular del cáncer

    Biología celular biomédica (Elsevier), pp. 375-407

  5. Correction to: Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease (Acta Neuropathologica, (2019), 138, 2, (251-273), 10.1007/s00401-019-02013-z)

    Acta Neuropathologica

  6. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  7. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  8. Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial

    The Lancet Neurology, Vol. 22, Núm. 2, pp. 127-136

  9. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2022

  1. Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown

    Nutrients, Vol. 14, Núm. 13

2021

  1. Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y6 receptor in mice

    Journal of Neuroinflammation, Vol. 18, Núm. 1

  2. The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy

    Science Translational Medicine, Vol. 13, Núm. 596

  3. The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration

    Cell Reports, Vol. 37, Núm. 13

  4. Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregation

    Journal of Biological Chemistry, Vol. 296

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

2019

  1. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease

    Acta Neuropathologica, Vol. 138, Núm. 2, pp. 251-273